News from GlycoVaxyn AG A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jul 01, 2014, 02:00 ET GlycoVaxyn announces the initiation of a Phase I clinical trial in collaboration with Janssen for a vaccine against Extra-intestinal pathogenic Escherichia coli causing urinary tract infection $countyNameToPathMap.put("sp

GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced the initiation of a Phase 1 clinical trial of a...


Jul 29, 2013, 07:00 ET GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine $countyNameToPathMap.put("sp

 Following recently signed collaborations with GlaxoSmithKline Biologicals (GSK) and Janssen Pharmaceuticals (JPI), GlycoVaxyn AG, a leader in...


Mar 06, 2013, 08:55 ET GlycoVaxyn AG anuncia la adición de Gerd Zettlmeissl como presidente del consejo de dirección $countyNameToPathMap.put("sp

Tras las recientes colaboraciones firmadas con GlaxoSmithKline Biologicals y Janssen Pharmaceuticals, GlycoVaxyn AG, líder en el desarrollo de...


Mar 06, 2013, 02:00 ET GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors $countyNameToPathMap.put("sp

 Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the...


Mar 06, 2013, 02:00 ET La société de biotechnologie Suisse GlycoVaxyn SA annonce la nomination de Gerd Zettlmeissl à la direction du Conseil d'Administration $countyNameToPathMap.put("sp

 Après la signature de deux collaborations avec GlaxoSmithkline et Janssen Pharmaceuticals, GlycoVaxyn SA, pionnier dans le...


Mar 06, 2013, 02:00 ET GlycoVaxyn AG ergänzt seinen Verwaltungsrat und ernennt Gerd Zettlmeissl zum Verwaltungsratspräsidenten $countyNameToPathMap.put("sp

 Nach den kürzlich angekündigten Kollaborationen mit GlaxoSmithKline Biologicals und Janssen Pharmaceuticals gibt GlycoVaxyn AG, ein...


Jan 04, 2013, 11:10 ET GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and Development Collaboration with Janssen Pharmaceuticals, Inc., to Develop Multi-Valent Bacterial Vaccine $countyNameToPathMap.put("sp

 GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Janssen Pharmaceuticals, Inc. (JPI), has signed an...


Dec 19, 2012, 07:00 ET La société de biotechnologie Suisse GlycoVaxyn SA annonce la signature d'un partenariat stratégique avec GSK afin de développer des vaccins anti-bactériens de nouvelle génération basés sur la technologie de bio conjugaison de GlycoVaxyn $countyNameToPathMap.put("sp

GlycoVaxyn SA, pionnier dans le développement de vaccins de nouvelle génération a rendu public aujourd'hui la signature d'un...


Dec 19, 2012, 07:00 ET GlycoVaxyn AG schliesst eine strategische Zusammenarbeit zur Entwicklung neuer bakterieller Impfstroffe mit GSK ab, welche auf GlycoVaxyn's Bio-Konjugationstechnologie basiert $countyNameToPathMap.put("sp

GlycoVaxyn AG, ein führendes Biotechunternehmen in der Entwicklung innovativer Impfstoffe hat heute eine Zusammenarbeit mit GlaxoSmithKline...


Dec 19, 2012, 07:00 ET GlycoVaxyn AG Announces Strategic Collaboration with GSK to Develop New Bacterial Vaccines using GlycoVaxyn's Bio-Conjugation Technology $countyNameToPathMap.put("sp

 GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced a collaboration with GlaxoSmithKline Biologicals (GSK) to...


Sep 16, 2011, 03:00 ET GlycoVaxyn's Staphylococcus aureus Bioconjugate Vaccine Candidate Protects Mice Against Invasive S. aureus Infection $countyNameToPathMap.put("sp

GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced an abstract to be presented on a glycoprotein vaccine based on...


Jun 15, 2011, 19:54 ET GlycoVaxyn veranstaltet zweiten jährlichen Wissenschaftstag zu Herausforderungen und Chancen im Bereich der Impfstoffentwicklung $countyNameToPathMap.put("sp

    GlycoVaxyn AG, ein im Bereich der Entwicklung konjugierter Impfstoffe führendes Unternehmen, gab heute bekannt, es werde seinen...


Jun 15, 2011, 19:52 ET GlycoVaxyn s'apprête à accueillir la deuxième Journée annuelle de la Science pour discuter des défis et des opportunités en matière de développement de vaccins $countyNameToPathMap.put("sp

    GlycoVaxyn AG, un chef de file dans le développement de vaccins conjugués, a aujourd'hui annoncé l'organisation de sa...


Jun 15, 2011, 05:00 ET GlycoVaxyn to Host Second Annual Science Day to Discuss Challenges and Opportunities in Vaccine Development $countyNameToPathMap.put("sp

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss...


Mar 05, 2009, 03:05 ET GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners $countyNameToPathMap.put("sp

- Proceeds to Facilitate Clinical Development of Lead Conjugate Vaccine GlycoVaxyn, a pioneer in the development of innovative...


May 20, 2008, 01:00 ET GlycoVaxyn Appoints Philippe Dro as CEO $countyNameToPathMap.put("sp

ZURICH-SCHLIEREN, Switzerland, May 20 /PRNewswire/ -- GlycoVaxyn AG, a pioneer in glycoengineering primarily developing innovative conjugated...